Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
John W FunderPrince Henry's Institute, Clayton, Victoria, AustraliaAbstract: Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much mo...
Saved in:
| 主要作者: | |
|---|---|
| 格式: | 圖書 |
| 出版: |
Dove Medical Press,
2013-10-01T00:00:00Z.
|
| 主題: | |
| 在線閱讀: | Connect to this object online. |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
| 索引號: |
A1234.567 |
|---|---|
| 復印件 1 | 可用 |